MX2012006376A - Peptidos mybl2 y vacunas que los contienen. - Google Patents
Peptidos mybl2 y vacunas que los contienen.Info
- Publication number
- MX2012006376A MX2012006376A MX2012006376A MX2012006376A MX2012006376A MX 2012006376 A MX2012006376 A MX 2012006376A MX 2012006376 A MX2012006376 A MX 2012006376A MX 2012006376 A MX2012006376 A MX 2012006376A MX 2012006376 A MX2012006376 A MX 2012006376A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- aforementioned
- inducibility
- cytotoxic
- fragments
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 abstract 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 abstract 1
- 101150008565 MYBL2 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26687109P | 2009-12-04 | 2009-12-04 | |
| PCT/JP2010/007028 WO2011067933A1 (en) | 2009-12-04 | 2010-12-02 | Mybl2 peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012006376A true MX2012006376A (es) | 2012-07-10 |
Family
ID=44114795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006376A MX2012006376A (es) | 2009-12-04 | 2010-12-02 | Peptidos mybl2 y vacunas que los contienen. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120328638A1 (https=) |
| EP (1) | EP2507257A4 (https=) |
| JP (1) | JP2013512659A (https=) |
| KR (1) | KR20120114284A (https=) |
| CN (1) | CN102753567A (https=) |
| AU (1) | AU2010327891A1 (https=) |
| BR (1) | BR112012013371A2 (https=) |
| CA (1) | CA2782484A1 (https=) |
| IL (1) | IL219927A0 (https=) |
| MX (1) | MX2012006376A (https=) |
| RU (1) | RU2012127762A (https=) |
| SG (1) | SG181108A1 (https=) |
| TW (1) | TW201200525A (https=) |
| WO (1) | WO2011067933A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623657B (zh) * | 2018-05-11 | 2021-02-12 | 苏州大学 | 多肽、重组dna分子、重组载体、外泌体及其应用 |
| AU2024251286A1 (en) * | 2023-04-07 | 2025-10-30 | Infinitopes Limited | Methods and compositions for cancer treatment using recombinant polypeptides |
| CN119859688B (zh) * | 2025-01-20 | 2026-03-17 | 杭州树源生命科学有限公司 | 环状RNA Hsa_circ_0006332在食管鳞状细胞癌诊断和治疗中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327786D1 (de) * | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| AU2003276167A1 (en) * | 2002-10-31 | 2004-05-25 | Janssen Pharmaceutica N.V. | Genes whose expression is increased in response to stimulation by corticotropin-releasing hormone |
| ES2364670T3 (es) * | 2005-02-25 | 2011-09-12 | Oncotherapy Science, Inc. | Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk. |
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
-
2010
- 2010-11-30 TW TW099141433A patent/TW201200525A/zh unknown
- 2010-12-02 RU RU2012127762/10A patent/RU2012127762A/ru not_active Application Discontinuation
- 2010-12-02 CN CN2010800635724A patent/CN102753567A/zh active Pending
- 2010-12-02 AU AU2010327891A patent/AU2010327891A1/en not_active Abandoned
- 2010-12-02 CA CA2782484A patent/CA2782484A1/en not_active Abandoned
- 2010-12-02 KR KR1020127017005A patent/KR20120114284A/ko not_active Withdrawn
- 2010-12-02 WO PCT/JP2010/007028 patent/WO2011067933A1/en not_active Ceased
- 2010-12-02 EP EP10834386A patent/EP2507257A4/en not_active Withdrawn
- 2010-12-02 US US13/513,543 patent/US20120328638A1/en not_active Abandoned
- 2010-12-02 BR BR112012013371A patent/BR112012013371A2/pt not_active IP Right Cessation
- 2010-12-02 SG SG2012039285A patent/SG181108A1/en unknown
- 2010-12-02 JP JP2012525550A patent/JP2013512659A/ja not_active Withdrawn
- 2010-12-02 MX MX2012006376A patent/MX2012006376A/es not_active Application Discontinuation
-
2012
- 2012-05-22 IL IL219927A patent/IL219927A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201200525A (en) | 2012-01-01 |
| CA2782484A1 (en) | 2011-06-09 |
| BR112012013371A2 (pt) | 2016-12-13 |
| AU2010327891A1 (en) | 2012-06-21 |
| SG181108A1 (en) | 2012-07-30 |
| EP2507257A4 (en) | 2013-04-03 |
| WO2011067933A1 (en) | 2011-06-09 |
| JP2013512659A (ja) | 2013-04-18 |
| CN102753567A (zh) | 2012-10-24 |
| IL219927A0 (en) | 2012-07-31 |
| KR20120114284A (ko) | 2012-10-16 |
| RU2012127762A (ru) | 2014-01-10 |
| US20120328638A1 (en) | 2012-12-27 |
| EP2507257A1 (en) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011673A (es) | Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal. | |
| MX2009009022A (es) | Vacunas de peptídicas para cánceres que expresan antígenos asociados con tumores. | |
| CR20200410A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027). | |
| EA201201305A1 (ru) | Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина для лечения рака желудка и других видов рака | |
| BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| NZ708990A (en) | Method for activating helper t cell | |
| MX366365B (es) | Peptidos de kntc2 y vacunas que los contienen. | |
| EP2528937A4 (en) | MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF | |
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| GB201019331D0 (en) | Methods for the diagnosis and treatment of cancer based on AVL9 | |
| MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| AR084095A1 (es) | Peptidos tomm34 y vacunas que los incluyen | |
| EP3208334A3 (en) | Cdc45l peptides and vaccines including the same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| MX2012006770A (es) | Peptidos tmem22 y vacunas que incluyen los mismos. | |
| BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |